A Phase 3 interventional study of Vitamin C and Placebo in Chronic Pain, Knee Pain Chronic and Post Operative Pain, sponsored by University Health Network, Toronto. Recruiting at 3 sites in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-13.
Sponsored by University Health Network, Toronto · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 19 studies in Chronic Pain by University Health Network, Toronto — 6 open to participants now, 10 under way, 3 of them phase 3. Chronic Pain · University Health Network, Toronto.
Among the 19 studies in Chronic Pain by University Health Network, Toronto, this one has the largest planned enrollment of the 15 interventional ones that give a count, is one of 2 that started in 2024, is one of 3 in phase 3, and was the 15th registered.
3,230 studies on the registry are indexed under Chronic Pain; 728 are open to participants now.
Browse Chronic Pain studies →6 of the 19 studies in Chronic Pain by University Health Network, Toronto are open now, in 1 country. Recruiting first, the newest first:
University Health Network, Toronto · Sites in Canada
Ages 18–80
University Health Network, Toronto · Sites in Canada
Ages 18–65
University Health Network, Toronto · Sites in Canada
Ages 18–75
University Health Network, Toronto · Sites in Canada
Ages 18–80
University Health Network, Toronto · Sites in Canada
Ages 18+
By country, each count listing its studies:
Of the 486 Chronic Pain studies recruiting now, 239 (49%) set no upper age limit and 173 (36%) stop at 75 or younger; 43 take children under 18; 64 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
19 studies; the count open now beside each. This study's row is marked.
First in 2012; this study’s year is marked. 2 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 3,216 is above the median of 60 across 2,388 interventional studies indexed under Chronic Pain.
Median enrollment 56 across the 15 interventional studies, 50 across the 4 observational. Of the 8 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
University Health Network, Toronto is the lead sponsor of 1,441 studies on the registry; 298 are open to participants now.
Of its 17 completed or terminated interventional studies of FDA-regulated products, 3 (18%) have results posted.
5 of the studies in Chronic Pain by University Health Network, Toronto that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05306899Phase 3University Health Network, TorontoMulti-center RCT of IV Ketamine Efficacy and Safety in Chronic Daily Headaches | 2027-02-01 |
| NCT03675386University Health Network, TorontoReducing Opioid Use for Chronic Pain Patients Following Surgery | 2026-12-31 |
| NCT07696741University Health Network, TorontoPRT for Chronic Low Back Pain | 2027-06 |
| NCT07818980University Health Network, TorontoCo-Adaptation of an Digital Pain Management Program for Canadian Veterans | 2027-09 |
| NCT07468591University Health Network, TorontoSpinal Cord Stimulation for Refractory Pain Randomized Controlled Trial: the PAcStim RCT | 2027-10-01 |
Add all 5 to your calendar (.ics) → With an account.
Among the 19 studies in Chronic Pain by University Health Network, Toronto, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Phase III Multicentre, parallel-group, blinded, 1:1 randomized controlled trial to determine the effect of perioperative vitamin C supplementation on reducing the prevalence of persistent pain 3 months after total knee arthroplasty.
PROVISION is a multicentre, parallel-group, blinded, randomized controlled trial of 3,216 patients undergoing total knee arthroplasty surgery. Consented eligible patients will be randomized to receive vitamin C: 2000 mg taken orally within 4 hours of the start of surgery, followed by 500 mg of vitamin C taken twice daily from post-operative day 1 to day 56 (8 weeks). Patient in the control group will receive placebo cellulose capsules. Study medications will be prepared to look similar and labelled as per regulatory requirements. Patients will follow up on post-operative days 1-3, weeks 2,4,6, and 8 post-operatively, and at 3- and 12-months post-operatively to report on pain, opioid and analgesic consumption, medication adherence, adverse events, physical and emotional functioning, and quality of life outcomes.
The criteria were revised on the registry on Nov 13, 2026. See what changed
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Preoperative Vitamin C capsules
Drug: Vitamin C
Preoperative placebo capsules
Drug: Placebo
Drug: Patients in the intervention group will receive 2g Vitamin C orally within 4 hours of the start of the surgery followed by 500 mg of Vitamin C to be taken orally twice a day from post-op day 1 to day 56.
Also known as: Ascorbic Acid
Drug: Patients in the placebo group will receive identical placebo capsules taken orally within 4 hours of the start of the surgery followed by placebo capsules taken orally twice a day from post-op day 1 to day 56.
Also known as: Cellulose
Prevalence of persistent pain
Pain intensity measured using 0-10 Numeric Rating Scale (NRS) scale at rest and movement
Time frame: 3 months
Prevalence of persistent pain
Pain intensity measured using 0-10 Numeric Rating Scale (NRS) scale at rest and movement
Time frame: 12 months
Qualities and characteristics of persistent pain
Pain qualities measured using the 0-10 scale of the Short Form McGill Pain Questionnaire 2 (SF-MPQ-2)
Time frame: 3 months and 12 months
Persistent Neuropathic Pain
Neuropathic pain assessed on a binary scale of Yes or No using the Douleur Neuropathique 4 (DN4) symptoms interview
Time frame: 3 months and 12 months
Acute and chronic analgesic consumption
Analgesic and oral morphine-equivalent opioid consumption
Time frame: Day of surgery, post-operative day 1-3, 3 months, and 12 months
Development of Complex Regional Pain Syndrome (CRPS)
Presence of CRPS measured by a physical assessment of sensory, vasomotor, sudomotor/edema, and motor/tropic categories using the Budapest Criteria
Time frame: 3 months and 12 months
Physical function
Patient reported outcome measure to assess level of function, daily living activities and their affect on pain measured by answering 12 questions using the Oxford Knee Score (OKS)
Time frame: 3 months and 12 months
Emotional functioning
Patients emotional functioning measured on a scale of 1-5 using the EQ-5D-5L
Time frame: 3 months and 12 months
Patient Satisfaction
Assessment of patient satisfaction with surgery on scale of 0-100
Time frame: 3 months and 12 months
Quality of life assessment
Patient reported assessment of mobility, self-care, usual activities, pain/discomfort, and anxiety/depression on a scale of level 1 - level 5 using the EuroQol 5-dimension 5-level (EQ-5D-5L)
Time frame: 3 months and 12 months
Adverse events
Monitored as a secondary safety outcome using an assessment of follow-up visits for drug related adverse events and passive surveillance of clinical notes
Time frame: 3 months and 12 months
Started Apr 2024 (actual). Primary completion is estimated for Dec 2029, 68 months after the start.
Of 49 phase 3 interventional studies under Chronic Pain, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 56. This study's planned 68 months is above that.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 13, 2026: primary completion Dec 2026 → Dec 2029 and completion Dec 2027 → Dec 2030.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ascorbic Acid
University Health Network, Toronto →